References
- Center for Behavioral Health Statistics and Quality. Results from the 2019 National Survey on Drug Use and Health: detailed tables. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2020.
- Black P, Joseph LJ. Still dazed and confused: midlife marijuana use by the baby boom generation. Deviant Behav. 2014;35(10):822–841.
- Choi NG, DiNitto DM, Marti CN. Older marijuana users’ marijuana risk perceptions: associations with marijuana use patterns and marijuana and other substance use disorders. Int Psychogeriatr. 2018;30(9):1311–1322.
- Han B, Compton WM, Blanco C, et al. Trends in and correlates of medical marijuana use among adults in the United States. Drug Alcohol Depend. 2018;186:120–129.
- Fairman BJ. Trends in registered medical marijuana participation across 13 US states and District of Columbia. Drug Alcohol Depend. 2016;159:72–79.
- Dai H, Richter KP. A national survey of marijuana use among US adults with medical conditions, 2016-2017. JAMA Netw Open. 2019;2(9):e1911936.
- Statista. Estimated dollar sales of the CBD market in the United States in 2019, by state. 2020. New York (NY); [cited 2020 Oct 15]. Retrieved from https://www.statista.com/statistics/1065838/dollar-sales-of-us-cbd-market-by-state/
- New frontier Data. Cannabis-infused products: U.S. consumer experience and demands. 2020. Washington (DC); [cited 2020 Oct 15]. Retrieved from https://newfrontierdata.com/product/the-cannabis-infused-products-report-series-u-s-consumer-experience-and-demand/
- U.S. Food & Drug Administration. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). 2020. Silver Spring (MD); [cited 2020 Oct 15]. Retrieved from https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
- Chandra S, Radwan MM, Majumdar CG, et al. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. 2019;269(1):5–15.
- Lafaye G, Karila L, Blecha L, et al. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017;19(3):309–316.
- Lewis MM, Yang Y, Wasilewski E, et al. Chemical profiling of medical cannabis extracts. ACS Omega. 2017;2(9):6091–6103.
- Roberts BA. Legalized cannabis in Colorado emergency departments: a cautionary review of negative health and safety Effects. West J Emerg Med. 2019;20(4):557–572.
- Pratt M, Stevens A, Thuku M, et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev. 2019;8(1):320.
- Monte AA, Shelton SK, Mills E, et al. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med. 2019;170(8):531–537.
- Grewal JK, Loh LC. Health considerations of the legalization of cannabis edibles. CMAJ. 2020;192(1):E1–E2.
- Noble MJ, Hedberg K, Hendrickson RG. Acute cannabis toxicity. Clin Toxicol. 2019;57(8):735–742.
- Foster BC, Abramovici H, Harris CS. Cannabis and cannabinoids: kinetics and interactions. Am J Med. 2019;132(11):1266–1270.
- Bass J, Linz DR. A case of toxicity from cannabidiol gummy ingestion. Cureus. 2020;12(4):e7688.
- Page RII, Allen LA, Kloner RA, et al. Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2020;142(10):e131–e152.
- Choi NG, Marti CN, DiNitto DM, et al. Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009-2019. Clin Toxicol. 2020;25:1–9.
- Riederer AM, Campleman SL, Carlson RG, et al. Acute poisonings from synthetic cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(27):692–695.
- Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018;43(1):34–51.
- Cuttler C, Mischley LK, Sexton M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannabinoid Res. 2016;1(1):166–175.
- Ste-Marie PA, Shir Y, Rampakakis E, et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain. 2016;157(12):2792–2797.
- Reynolds IR, Fixen DR, Parnes BL, et al. Characteristics and patterns of marijuana use in community-dwelling older adults. J Am Geriatr Soc. 2018;66(11):2167–2171.
- Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th annual report. Clin Toxicol. 2019;57(12):1220–1413.
- Alsherbiny MA, Li CG. Medicinal cannabis-potential drug interactions. Medicines. 2018;6(1):3.
- Brown JD, Costales B, van Boemmel-Wegmann S, et al. Characteristics of older adults who were early adopters of medical cannabis in the Florida Medical Marijuana Use Registry. JCM. 2020;9(4):1166.
- Choi NG, DiNitto DM, Marti CN. Older-adult marijuana users and ex-users: comparisons of sociodemographic characteristics and mental and substance use disorders. Drug Alcohol Depend. 2016;165:94–102.